WHO ICTRP trial
A study to see if the drug Lu-177 trastuzumab can be used to treat patinets with…
CTRI/2023/05/053068 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2023/05/053068 |
|---|---|
| Public title | A study to see if the drug Lu-177 trastuzumab can be used to treat patinets with HER-2 positive cancer breast |
| Scientific title | Pilot study to evaluate the role Lu-177 Trastuzumab in patients with HER2 positive metastatic carcinoma breast |
| Primary sponsor | Ashok Kumar |
| Secondary sponsors | Nandini Pandit |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: C509- Malignant neoplasm of breast of unspecified site |
| Interventions | Intervention1: Lu-177 trastuzumab therapy: Lu-177 is a type of radioimmunotherapy where the Radiation emitting agent LU-177 is combined with the monocolnal antibody trastuzumab. Lu-177 trastuzumab congujate bind to the sites expressing HER2… |
| Registration date | May 23, 2023 |
| Target size | 12 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: